Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 February 27, 2023
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 15, 2022
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting November 8, 2022
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors September 2, 2022
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights August 12, 2022
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights May 11, 2022
